What does Mosanna Therapeutics do?
Mosanna Therapeutics is a Redwood City-based clinical-stage biotech company that develops innovative pharmaceutical treatments for obstructive sleep apnea using an easily administered nasal spray designed to restore the body's natural airway control during sleep.
How much did they raise?
The company raised $80M in Series A funding, led by Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Broadview Ventures, and Norwest, with additional participation from Forty51 Ventures, Supermoon Capital, and High-Tech Gründerfonds (HTGF).
What are their plans for the money?
The funds will be used to advance MOS118 into Phase 2 development while also supporting the expansion of Mosanna's product pipeline, potentially offering a less invasive alternative to traditional mechanical treatments for OSA.
What have they achieved so far?
Mosanna Therapeutics has already made progress with MOS118, which is currently under evaluation in a Phase 1 clinical trial, marking an important milestone in its mission to revolutionize OSA treatment.
